BiVictriX Therapeutics PLC Expansion of Therapeutic Pipeline (4803C)

TIDMBVX

RNS Number : 4803C

BiVictriX Therapeutics PLC

23 February 2022

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or "the Company")

BiVictriX announces expansion of its therapeutic pipeline with two additional drug discovery programmes

Alderley Park, 23 February 2022 - BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, today announces the expansion of the Company's therapeutic pipeline with two additional programmes, BVX002 and BVX003, both entering the early stages of drug development.

BVX002 and BVX003 target novel cancer-specific twin antigen fingerprints, incorporating the Company's proprietary Bi-Cygni(R) technology, alongside the established and validated Antibody Drug Conjugate (ADC) mechanism-of-action, to form the next-generation of Bi-Cygni(R) ADCs with superior cancer selectivity. These programmes enable the targeting of several haematological and solid tumour cancer indications and will be developed alongside BiVictriX's lead asset, BVX001, which has a lead indication in Acute Myeloid Leukaemia (AML). This pipeline expansion demonstrates the broad utility of the Bi-Cygni(R) approach across a wide range of solid tumour and haematological cancer types which constitute areas of significant unmet medical need, and further highlights the potential expansion of the platform in novel areas of immuno-oncology.

The pipeline expansion follows the Company's recent filing of four new patent applications to further strengthen its growing intellectual property portfolio in the UK and internationally. The patents, which will form part of a new patent family for BiVictriX, relate to several novel cancer-specific antigen pairs or "fingerprints" across a range of oncology indications, which have been identified by the Company.

Tiffany Thorn, Chief Executive of BiVictriX, commented: "This is an exciting announcement for the Company. The expansion of our current therapeutic pipeline to include two additional programmes moving into the early stages of development is a significant milestone and enables BiVictriX to demonstrate the broad utility of its promising new approach to cancer therapeutic development across a wide range of difficult-to-treat cancers, including both solid tumour and haematological indications that currently represent areas of urgent unmet medical need. We are focused on working to fast-track the development of these two new programmes alongside our lead asset, BVX001, to reach early preclinical proof of concept in the short to medium term."

 
   For more information, please contact: 
     BiVictriX Therapeutics plc 
     Tiffany Thorn, Chief Executive Officer    Email: [e-mail] 
      Iain Ross, Chairman 
 
     SP Angel Corporate Finance LLP (NOMAD     Tel: [phone] 
      and Broker)                               0470 
     David Hignell, Caroline Rowe (Corporate 
      Finance) 
      Vadim Alexandre, Rob Rees (Sales and 
      Broking) 
     Panmure Gordon (UK) Limited (Joint        Tel: [phone] 
      Broker)                                   2500 
     Rupert Dearden/Freddy Crossley/Emma 
      Earl 
      Consilium Strategic Communications 
     Mary-Jane Elliott, Genevieve Wilson,      Tel: [phone] 
      Alex Gunter                               Email: [e-mail] 
 

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst eliminating treatment-related toxicities.

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni(R) therapeutics which are designed to selectively target antigen co-expression fingerprints, or "twin antigens", on tumour cells, which are largely absent from healthy cells. Whereas this concept has been validated in a clinical diagnostic setting to support the diagnosis and monitoring of haematological cancers, it has not yet been widely used in a therapeutic setting.

BiVictriX has identified a diverse panel of novel cancer-specific "twin antigens", across a broad range of cancer indications including Diffuse Large B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm. The Company is using these novel "twin-antigens" to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and currently constitute areas of high unmet medical need.

Find out more about BiVictriX online at www.bivictrix.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCSEIFWEEESEEE

(END) Dow Jones Newswires

February 23, 2022 02:00 ET (07:00 GMT)